Clinical Trials Browser

Phase 2 × UNKNOWN × Breast × Clear all

Breast Neoplasms

NCT05546255 2022-09-19

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Phase 2 Unknown

40 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05089643 2022-01-10

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Phase 2 Unknown

35 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05154396 2021-12-13

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Phase 2 Unknown

60 enrolled

Breast

HER2-positive Breast Cancer

NCT05020964 2021-08-25

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

Phase 2 Unknown

68 enrolled

Breast

Advanced Breast Cancer

NCT04452370 2021-07-21

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

Phase 2 Unknown

100 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03535961 2020-12-02

Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer

Phase 2 Completed

32 enrolled

Breast

Breast Neoplasms

NCT04002284 2020-07-29

Anlotinib in Metastatic HER2 Negative Breast Cancer

Phase 2 Completed

26 enrolled

Breast

Breast Neoplasms

NCT03933319 2020-07-08

Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer

Phase 2 Unknown

30 enrolled

Breast

HER2-positive Breast Cancer

NCT03939871 2020-06-23

A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

Phase 2 Unknown

30 enrolled

Breast

Hormone Receptor Positive Advanced Breast Cancer

NCT04437160 2020-06-18

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

Phase 2 Recruiting

286 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04194684 2019-12-11

Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer

Phase 2 Unknown

108 enrolled

Breast

Breast Neoplasms

NCT04033172 2019-07-25

Pyrotinib

Phase 2 Unknown

40 enrolled

Breast

Breast Neoplasms

NCT02768415 2019-06-19

Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer

Phase 2 Unknown

40 enrolled

Breast

Breast Neoplasms

NCT03933982 2019-05-29

Pyrotinib

Phase 2 Unknown

30 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03923166 2019-04-22

Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer

Phase 2 Unknown

35 enrolled

Breast

Breast Neoplasms

NCT03923179 2019-04-22

Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

Phase 2 Unknown

32 enrolled

Breast

Breast Neoplasms

NCT03735082 2018-11-08

Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer

Phase 2 Unknown

29 enrolled

Breast

Breast Neoplasms

NCT02646735 2017-01-02

FRIEND

Phase 2 Unknown

148 enrolled

Breast

Breast Neoplasms

NCT02947061 2016-10-31

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

Phase 2 Unknown

300 enrolled

Breast

Breast Cancer Recurrent

NCT02934828 2016-10-18

Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer

Phase 2 Unknown

230 enrolled

Breast

Breast Neoplasms

NCT02829008 2016-07-12

Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

Phase 2 Unknown

120 enrolled

Breast

Breast Neoplasms

NCT02460744 2015-06-02

2-weeks of Adjuvant Radiotherapy in Patients With Breast Cancer

Phase 2 Completed

50 enrolled

Breast

Breast Neoplasms

NCT01928680 2015-02-23

Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer

Phase 2 Unknown

33 enrolled 5 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02041338 2014-11-25

Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer

Phase 2 Unknown

200 enrolled

Breast

Breast Neoplasms

NCT01492556 2013-03-15

Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer

Phase 2 Unknown

100 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT01431053 2013-03-13

Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer

Phase 2 Unknown

160 enrolled

Breast

Breast Neoplasms

NCT01276769 2011-11-16

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

Phase 2 Unknown

80 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BC

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer

Anlotinib in Metastatic HER2 Negative Breast Cancer

Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer

A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer

Pyrotinib

Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer

Pyrotinib

Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer

Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer

FRIEND

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer

Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

2-weeks of Adjuvant Radiotherapy in Patients With Breast Cancer

Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer

Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer

Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer

Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer